Previous symbols: BZS, MHAM. Aliases: MMAC1, TEP1, PTEN1.
PTEN (phosphatase and tensin homolog) is named by 21 disorder entries.
ai-gene-review gives PTEN's core molecular functions as phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase activity; phosphatidylinositol-3,4-bisphosphate 3-phosphatase activity; and protein serine/threonine phosphatase activity, acting in negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; phosphatidylinositol dephosphorylation; and protein dephosphorylation.
Two entries type PTEN as causative: Bannayan-Riley-Ruvalcaba Syndrome; and Familial Nonmedullary Thyroid Carcinoma, and both record the variants as germline (Bannayan-Riley-Ruvalcaba Syndrome; and Familial Nonmedullary Thyroid Carcinoma). In Bannayan-Riley-Ruvalcaba Syndrome the gene sits on the node Germline PTEN Loss of Function.
The two entries most closely identified with the gene record it differently.
Cowden Syndrome's genetic record is
untyped,
as is PTEN Hamartoma Tumor Syndrome's
(untyped):
both say "Causative" only in the free-text association field, and neither
records a variant origin
(unrecorded). ClinGen rates
PTEN
definitive
for PTEN hamartoma tumor syndrome, so that entry's record could be typed causative
without any new evidence. Cowden Syndrome
nonetheless places PTEN on
6
pathophysiology nodes, including
PTEN Loss and PI3K/AKT/mTOR Pathway Activation
and PTEN Genome Integrity Defect.
Nodes naming PTEN in these syndromes conform to the module
germline_two_hit_tumor_predisposition.
Three entries type PTEN as a somatic driver: Chromophobe Renal Cell Carcinoma; Endometriosis; and Thyroid Follicular Carcinoma. Two of them record the variant origin as somatic (Chromophobe Renal Cell Carcinoma; and Endometriosis); Thyroid Follicular Carcinoma's is unrecorded. Several carcinoma entries carry PTEN with no relationship type, among them Endometrial Carcinoma; Prostate Adenocarcinoma; and Glioblastoma, IDH-Wildtype; for example Endometrial Carcinoma is untyped.
ClinGen classifies PTEN for 1 disease, and the dismech entries matched to it that do not type the gene are PTEN Hamartoma Tumor Syndrome.
Of the disorders that name PTEN,
14
have a genetic record for it with no relationship_type. That is the main
curation gap this page exposes.
The KB's PTEN nodes are annotated with the PI3K/AKT process itself, while ai-gene-review annotates PTEN with the negative regulation of that process, so the two share 0 GO terms by exact identifier. Reading the KB annotation as "PTEN loss increases PI3K/AKT signalling" and the ai-gene-review one as "PTEN normally restrains it" reconciles them; a closure-aware comparison would need the GO hierarchy.
Underlined values are claims re-computed from the knowledge base each time this page is built. The tables below are the source of truth.
PTEN (Phosphatase and Tensin Homolog) is a critical tumor suppressor encoding a dual-specificity phosphatase with both lipid and protein phosphatase activities. Its primary and essential tumor suppressor function is as a phosphatidylinositol-3,4,5-trisphosphate (PIP3) 3-phosphatase that dephosphorylates PIP3 to PIP2, thereby antagonizing PI3K/AKT/mTOR signaling. PTEN also exhibits protein phosphatase activity against serine, threonine, and tyrosine residues, though the lipid phosphatase activity is the critical determinant of tumor suppression. Nuclear PTEN contributes to genomic stability and cell cycle control. PTEN localizes to the plasma membrane, cytosol, and nucleus, with membrane localization mediated by its C2 domain and PDZ-binding motif interactions with scaffold proteins like MAGI-2. Germline mutations cause PTEN Hamartoma Tumor Syndrome (PHTS/Cowden disease), while somatic mutations occur frequently across many cancer types.
Relationship is the entry's genetic[].relationship_type. untyped means the entry has a genetic record for the gene but does not type it; its free-text association is shown instead.
| Disorder | Relationship | Where the gene appears |
|---|---|---|
| Bannayan-Riley-Ruvalcaba Syndrome | causative germline |
mechanism: Germline PTEN Loss of Function
variant: PTEN p.Arg130Ter; PTEN p.Arg233Ter; PTEN p.Arg335Ter
|
| Chromophobe Renal Cell Carcinoma | somatic driver somatic | |
| Endometriosis | somatic driver somatic | |
| Familial Nonmedullary Thyroid Carcinoma | causative germline | |
| Thyroid Follicular Carcinoma | somatic driver |
mechanism: MAPK and PI3K-AKT Pathway Activation
|
| BRAF V600E-Mutant Colorectal Cancer |
untyped
Co-occurring Loss of Function
|
|
| Chordoma |
untyped
Somatic Pathway Activation
|
|
| Cowden Syndrome |
untyped
Causative
|
mechanism: Hamartoma Formation; Increased Cancer Risk; Neurodevelopmental Cortical Dysfunction; PTEN Genome Integrity Defect; PTEN Loss and PI3K/AKT/mTOR Pathway Activation; Reduced Succinate Dehydrogenase Activity
subtype: CS1
animal model: Epithelial-specific Pten deletion (colorectal juvenile polyposis); Mammary Pten loss with constitutive Stat5 activation; Neuronal Pten deletion (macrocephaly and social-behaviour phenotypes)
scoped to subtype: CS1
|
| Cutaneous Melanoma |
untyped
Somatic loss of function
|
|
| Endometrial Carcinoma |
untyped
Somatic loss-of-function mutation
|
mechanism: PTEN PI3K Pathway Dysregulation
|
| Endometrial Endometrioid Adenocarcinoma |
untyped
Recurrent somatic driver alteration
somatic
|
mechanism: PTEN PI3K Pathway Dysregulation
|
| Gastroenteropancreatic Neuroendocrine Neoplasm |
untyped
Inactivating mutations in ~7% of pancreatic NETs; mTOR pathway component
|
|
| Glioblastoma, IDH-Wildtype |
untyped
Loss/Mutation
|
|
| Juvenile Polyposis Syndrome |
untyped
Subtype-specific contiguous deletion partner
|
|
| Melanoma_in_Congenital_Melanocytic_Nevus |
untyped
Loss of function
|
mechanism: PI3K-AKT-mTOR Pathway Activation
|
| Ovarian Endometrioid Carcinoma |
untyped
Loss-of-function mutation
|
mechanism: PI3K-AKT Pathway Activation
|
| Pancreatic Neuroendocrine Tumor |
untyped
Inactivating mutations in ~7% of pNETs; mTOR pathway component
|
|
| Prostate Adenocarcinoma |
untyped
Somatic loss or deletion
|
|
| PTEN Hamartoma Tumor Syndrome |
untyped
Causative
|
mechanism: PTEN loss and PI3K AKT mTOR activation
|
| BRAF V600 Mutant Melanoma | no genetic record |
mechanism: PTEN-Loss and PI3K-AKT-mTOR Cooperation
animal model: Mus musculus
|
| Neurofibromatosis Type 1 | no genetic record |
mechanism: Malignant Peripheral Nerve Sheath Tumor Progression
|
An entry matches when ClinGen's MONDO disease is the entry's own disease term, a subtype term, or an exact-match mapping. An amber status marks an entry ClinGen supports the gene for (Definitive, Strong or Moderate) whose own record does not type it. A Limited, Disputed or Refuted tier on such an entry is not a gap.
| ClinGen disease | MOI | Classification | dismech entry |
|---|---|---|---|
| PTEN hamartoma tumor syndrome MONDO:0017623 | AD | Definitive 2024-04-05 |
PTEN Hamartoma Tumor Syndrome
untyped
|
Identity from HGNC (snapshot 2026-10-01). Page layers are described in the gene pages documentation.